ABVC BioPharma, Inc.
ABVC
$2.77
$0.04011.47%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 240.57% | 118.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 231.17% | 81.56% | |||
| Operating Income | -231.17% | -82.51% | |||
| Income Before Tax | -144.57% | -832.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -147.07% | -832.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -25.76% | 1.69% | |||
| Net Income | -168.02% | -467.25% | |||
| EBIT | -231.17% | -82.51% | |||
| EBITDA | -233.57% | -85.76% | |||
| EPS Basic | -130.55% | -423.56% | |||
| Normalized Basic EPS | -152.46% | -272.32% | |||
| EPS Diluted | -130.55% | -423.56% | |||
| Normalized Diluted EPS | -152.46% | -272.32% | |||
| Average Basic Shares Outstanding | 16.16% | 13.36% | |||
| Average Diluted Shares Outstanding | 16.16% | 13.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||